Return to Home Incidence > Table

Incidence Rates Table

Data Options

Incidence Rate Report by State

Kidney & Renal Pelvis (Late Stage^), 2017-2021

All Races (includes Hispanic), Both Sexes, All Ages

Sorted by Percentlate

State
 sort alphabetically by name ascending
Age-Adjusted Incidence Rate
cases per 100,000
(95% Confidence Interval)
 sort by rate descending
CI*Rank
(95% Confidence Interval)
 sort by CI rank descending
Average Annual Count
 sort by count descending
Percent of Cases with Late Stage
 sort by percent late ascending
US (SEER+NPCR) 1 4.9 (4.8, 4.9) N/A 19,323 28.7
New Mexico 3 5.6 (5.2, 6.0) 8 (2, 25) 149 35.2
Wyoming 6 5.3 (4.6, 6.1) 18 (1, 44) 39 35.1
Vermont 6 5.2 (4.5, 5.9) 24 (2, 45) 47 34.3
Rhode Island 6 5.5 (5.0, 6.1) 10 (1, 31) 77 33.4
Hawaii 3 4.3 (3.9, 4.8) 44 (25, 49) 83 32.9
Maine 6 5.3 (4.9, 5.8) 17 (3, 32) 108 31.6
Iowa 3 6.1 (5.8, 6.5) 2 (1, 11) 253 31.2
Minnesota 6 5.5 (5.3, 5.8) 9 (5, 23) 383 30.9
California 3 4.5 (4.5, 4.6) 37 (29, 42) 2,043 30.8
Washington 5 4.7 (4.5, 4.9) 29 (23, 41) 428 30.8
Ohio 6 5.4 (5.2, 5.6) 13 (7, 23) 812 30.7
Illinois 3 5.4 (5.2, 5.6) 12 (7, 23) 842 30.3
South Dakota 6 5.3 (4.7, 6.0) 19 (2, 42) 58 30.0
Nebraska 6 5.4 (4.9, 5.8) 15 (4, 29) 124 29.5
West Virginia 6 6.1 (5.6, 6.5) 3 (1, 15) 154 29.5
Wisconsin 6 5.5 (5.3, 5.7) 11 (5, 24) 422 29.5
Connecticut 3 4.6 (4.3, 4.8) 36 (24, 45) 212 29.4
Michigan 6 4.7 (4.5, 4.9) 30 (24, 41) 613 29.4
New Jersey 3 4.6 (4.4, 4.8) 34 (26, 43) 530 29.4
Georgia 3 5.2 (5.0, 5.4) 22 (11, 27) 629 29.3
Missouri 6 5.7 (5.4, 5.9) 7 (3, 20) 440 29.2
Oregon 6 4.4 (4.2, 4.7) 41 (27, 46) 243 29.2
Oklahoma 6 6.0 (5.7, 6.3) 4 (1, 12) 283 29.1
Alaska 6 5.4 (4.6, 6.2) 14 (1, 44) 42 29.0
Montana 6 4.9 (4.3, 5.4) 27 (8, 45) 70 28.6
Texas 3 5.8 (5.7, 6.0) 6 (2, 10) 1,748 28.6
Utah 3 4.4 (4.1, 4.8) 40 (24, 47) 130 28.6
Kentucky 3 5.9 (5.6, 6.2) 5 (1, 14) 334 28.3
Pennsylvania 6 4.6 (4.4, 4.7) 35 (27, 43) 794 28.3
Arizona 6 4.5 (4.3, 4.7) 38 (26, 45) 407 28.2
New York 3 4.6 (4.5, 4.7) 33 (27, 42) 1,151 28.2
Florida 6 4.3 (4.2, 4.4) 43 (38, 45) 1,318 28.1
Louisiana 3 6.4 (6.1, 6.7) 1 (1, 5) 360 28.1
New Hampshire 6 4.6 (4.2, 5.1) 32 (17, 47) 89 28.0
North Dakota 6 5.2 (4.5, 5.9) 23 (2, 44) 48 27.8
Kansas 6 5.4 (5.0, 5.7) 16 (4, 28) 185 27.4
Colorado 6 3.9 (3.7, 4.2) 47 (43, 50) 256 27.1
South Carolina 6 4.7 (4.4, 4.9) 31 (23, 43) 309 27.1
North Carolina 6 5.0 (4.8, 5.1) 26 (19, 31) 639 26.8
Nevada 6 3.6 (3.4, 3.9) 49 (45, 50) 134 26.4
Idaho 3 4.8 (4.4, 5.2) 28 (14, 45) 103 26.3
District of Columbia 6 3.2 (2.6, 3.8) 50 (45, 50) 22 25.8
Tennessee 6 5.1 (4.8, 5.3) 25 (14, 30) 434 25.8
Arkansas 6 5.3 (4.9, 5.6) 21 (7, 29) 197 25.5
Maryland 6 3.9 (3.7, 4.1) 48 (44, 50) 292 25.5
Virginia 6 4.0 (3.8, 4.2) 46 (43, 49) 416 25.4
Mississippi 6 5.3 (4.9, 5.6) 20 (6, 29) 193 24.7
Alabama 6 4.4 (4.2, 4.6) 42 (28, 46) 279 24.3
Delaware 6 4.1 (3.6, 4.7) 45 (25, 50) 54 24.2
Puerto Rico 6 2.1 (1.9, 2.3) N/A 88 24.0
Indiana 6
data not available
N/A
data not available
data not available
Notes:
Created by statecancerprofiles.cancer.gov on 12/07/2024 7:22 pm.

State Cancer Registries may provide more current or more local data.
Trend
Rising when 95% confidence interval of average annual percent change is above 0.
Stable when 95% confidence interval of average annual percent change includes 0.
Falling when 95% confidence interval of average annual percent change is below 0.

† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.

^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.
⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.

Data not available for this combination of data selections.
1 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2023 submission.
3 Source: SEER November 2023 submission. State Cancer Registry also receives funding from CDC's National Program of Cancer Registries.
5 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2023 submission.
6 Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2023 submission).

Data for the United States does not include data from Indiana.
Data for the United States does not include Puerto Rico.
CI*Rank data for Puerto Rico is not available.

Return to Top